Skip to content
MARKETS / NASDAQ / LAB
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Standard Biotools Inc. LAB

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$85.3M
▼ 6.2% YoY
$-74.9M
$-82.6M
In brief

What this company does

It currently participates in emerging segments of the life sciences research and biopharmaceutical tools market focused on proteomics and genomics. The company was incorporated in California in May 1999 as Mycometrix Corporation, changed its name to Fluidigm Corporation in April 2001, and reincorporated in Delaware in July 2007. On April 1, 2022, the company changed its name from Fluidigm Corporation to Standard BioTools Inc. As of December 31, 2025, the company had a total of 389 employees worldwide, excluding employees associated with discontinued operations, of which 385 were full-time employees and 96 were located in the United States.

Written from the business description in Standard BioTools Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth
USD 85.3M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 85.3 · Net income -74.9
50M100M-80M-160M200920112013201520172019202120232025
Compound annual growth
−4.5%
−9.2%
−2.9%
+6.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −9.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−88 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -129.2% · Net -87.8%
-50%-100%-150%200920112013201520172019202120232025
ROE
FY2025 · ROE -16.7%
-1000%-2000%200920112013201520172019202120232025

Each USD of equity lost 17 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -82.6
-80M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks -0.5
20M20212022202320242025

Total assetsUSD 567.8M
EquityUSD 424.3M
CashUSD 120.9M
Current ratio4.19×

Equity funds 75% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.10.10.10.10.10.10.10.10.10.10.10.10.10.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.00.0−0.0
Net income $B−0.1−0.1−0.1−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.2−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.20−0.52−0.94−2.43−0.78−0.74−0.97−1.49−1.84−2.62−1.86−1.90−0.65−0.86−1.81−8.94−11.02
Dividend / sh $·················
Payout %·················
ROE %−16.7−85.8·−2895.8−50.7−36.2−57.4−114.5−143.8−90.4−40.2−42.8−16.8−24.1···
Shares out B0.390.380.080.080.080.070.070.050.040.030.030.030.030.030.020.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 73 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 15 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image